QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) Completes Historic REVIVE Trial, Sets Stage for Long COVID Breakthrough and Market Expansion
Fifty 1 Labs (OTC: FITY), through its subsidiary Fifty1 AI Labs, LLC, announced the successful completion of the REVIVE Adaptive Platform Trial (NCT06128967), a groundbreaking Phase III study and the largest Long COVID trial to date. Conducted with global partners and top institutions including Stanford and Duke, the randomized, double-blind trial enrolled over 600 participants and demonstrated a clear treatment benefit using repurposed medicines. Powered by FITY’s proprietary AI platform, the trial sets a new standard in drug repurposing and personalized medicine, while supporting the company’s broader strategy to lead the $320.6 billion functional medicine market, pursue strategic acquisitions, and…